Lurbinectedin is a chemotherapy drug that is currently used for the treatment of certain types of cancer, such as small cell lung cancer and metastatic breast cancer. However, there is limited information available on the safety of lurbinectedin for infants.

According to the Drug Patent Watch [1], there is no information available on the use of lurbinectedin in infants, and the drug is not recommended for use in pediatric patients. This suggests that lurbinectedin has not been tested in infants and its safety in this population is unknown.

Similarly, the Children's Hospital of Philadelphia [2] does not provide any information on the use of lurbinectedin in infants. However, the hospital's website does state that chemotherapy drugs can be particularly toxic to infants and young children, and that dosages must be carefully calculated to avoid toxicity.

The FDA [3] has approved lurbinectedin for the treatment of certain types of cancer in adults, but the drug's safety in infants has not been established. The FDA's prescribing information for lurbinectedin does not provide any dosing recommendations for pediatric patients, including infants.

In conclusion, there is currently no information available on the safety of lurbinectedin for infants. The drug is not recommended for use in pediatric patients, and its use in infants should be carefully considered and monitored by a healthcare professional. Further research is needed to determine the safety and efficacy of lurbinectedin in this population.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.research.chop.edu/taxonomy/term/7135
[3] https://www.fda.gov/media/105933/download